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Background/Aims: The aim of this study was to evaluate 
the usefulness of health screening for early detection and 
improved prognosis in pancreatic cancer. Methods: Between 
1995 and 2008, 176,361 examinees visited the Health 
Promotion Center (HPC). Twenty patients diagnosed with 
pancreatic cancer were enrolled. During the same period, 40 
patients were randomly selected from 2,202 patients diag-
nosed with pancreatic cancer at the Out Patient Clinic (OPC) 
for comparison. Results: Within the HPC group, 10 patients 
were initially suspected of having pancreatic cancer follow-
ing abnormal ultrasonographic ﬁ  ndings, and 9 patients had 
suspected cases following the detection of elevated serum 
CA 19-9. The curative resection rate was higher in the HPC 
group than in the OPC group (p=0.011). The median survival 
was longer in the HPC group than in the OPC group (p=0.000). 
However, there was no significant difference in the 3-year 
survival rate between the two groups. Asymptomatic patients 
(n=6/20) in the HPC group showed better curative resec-
tion and survival rates than symptomatic patients. However, 
the difference was not statistically signiﬁ  cant. Conclusions: 
Health screening is somewhat helpful for improving the cura-
tive resection rate and median survival of patients with pan-
creatic cancer detected by screening tests. However, the ben-
eﬁ  t of this method in improving long-term survival is limited 
by how early the cancer is detected. (Gut Liver 2011;5:194-
199)
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INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer death 
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in most Western countries. Actually, an estimated 42,470 new 
cases of pancreatic cancer are expected to occur and an esti-
mated 35,240 deaths are expected to occur in the United States 
during 2009.
1
The prognosis of pancreatic cancer is very poor. For all stages 
combined, the 5-year survival rate is 5% and even for those 
people diagnosed with resectable disease, the 5-year survival 
rate is only 20%. Approximately only 20% of patients have dis-
ease amendable to surgical resection at the time of presentation.
2 
In addition, a subset of patients undergoing curative resection 
(up to 30%) will have positive resection margins, reflecting an 
incomplete resection. Eventually less than 10% of patients with 
pancreatic cancer undergo a margin-negative (R0) resection.
3 
The dismal prognosis of this disease is due to the silent nature of 
pancreatic cancer until late in the disease process.
4 Patients pres-
ent for a medical evaluation only when the cancer is advanced; 
this is when they experience the signs and symptoms of obstruc-
tive jaundice, abdominal pain, and weight loss. 
The only hope for long-term survival in pancreatic cancer 
is a curative resection. While some progress has been made in 
chemotherapy of pancreatic cancer and newer biologic agents 
promise better results, overall adjuvant therapy only prolongs 
life and rarely cures pancreatic cancer.
5 Therefore, early detec-
tion and curative resection are important strategies to improve 
outcomes. Unfortunately, there is no rationale to investigate 
early detection strategies in the general population owing to the 
relatively low incidence of pancreatic cancer and the lack of 
cost-effective screening tool.
6 
Recently, as the public awareness about health has increased, 
general health screening is becoming increasingly popular. 
These health screenings are being periodically conducted by 
individuals, welfare program in workplace, or health insurance 
companies. Since a health screening program is not only for 
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the detection of pancreatic cancer but also for general health 
screening including all kinds of cancer and metabolic disorders, 
the cost-effectiveness related to the early detection of pancreatic 
cancer is not an important issue under this screening program. 
So, in this study, we evaluated whether the health screening 
was useful for the early detection and improving the prognosis 
of pancreatic cancer.
MATERIALS AND METHODS
Twenty patients were diagnosed with pancreatic cancer 
among 176,361 healthy examinees visiting the Health Promo-
tion Center (HPC) at Samsung Medical Center, Seoul, Korea, 
from 1995 to 2008. There were seven missed cases thought to 
be benign conditions of the pancreas at the health promotion 
center, but diagnosed with pancreatic cancer within one year 
thereafter. During the same period, among 2,202 patients that 
were diagnosed with pancreatic cancer at the Out Patient Clinic 
(OPC) of Samsung Medical Center, 40 patients (two times more 
than HPC group) were randomly selected for comparison after 
matching for age and gender to the HPC. This study was ap-
proved by the Institutional Review Board of Samsung Medical 
Center.
The following data from a self administered questionnaire 
and/or physical examination by physicians were collected: age, 
gender, history of smoking and alcohol, a medical history such 
as diabetes and chronic pancreatitis, family medical history, 
body mass index (BMI), and whether a specific symptom was 
present or absent. BMI was calculated by dividing the weight (kg) 
by height (m
2) on the basis of the usual weight before losing 
weight. In addition, the medical records on pancreatic cancer 
such as modality of diagnosis, imaging finding, tumor stage, 
resection status, and survival rate were reviewed. The CA 19-9 
level, as a tumor marker was collected. The upper limit of the 
normal range of CA 19-9 was defined as 37 U/mL, as suggested 
by Del Villano et al.
7 The modality of diagnosis was an initial 
test used for a suspected diagnosis of pancreatic cancer. If sur-
gery was impossible, the tumor stage was determined based on 
the imaging finding. If surgery was performed, the tumor stage 
was determined by the clinical staging system of the American 
Joint Committee on Cancer (AJCC) TNM classification. A cura-
tive resection was defined as a margin-negative (R0) resection 
by microscopy. 
Statistical analysis was performed using the χ
2 test for com-
parison of discrete variables and the t-test was used for com-
parison of continuous variables. The BMI measured in this study 
was expressed as the median. Statistical analysis was performed 
using PASW Statistics 17.0 (SPSS Inc., Chicago, IL, USA). All 
p-values were two-tailed and a value of p<0.05 was considered 
significant. 
RESULTS
1. Clinical characteristics
The median age of HPC and OPC groups was 64 years (range, 
47 to 82 years) and 65 years (range, 42 to 86 years), respec-
tively. The ratio of men to women was 2.3:1 in both groups. 
While all patients in the OPC group had presenting symptoms, 6 
patients in the HPC group were asymptomatic at the time of di-
agnosis (p=0.031). The common symptoms were abdominal pain 
(35% vs 57.5%), weight loss (40.0% vs 35%), back pain (20% vs 
12.5%), and jaundice (0% vs 10%) in each group (HPC group vs 
OPC group) (Table 1). Table 2 shows the risk factors associated 
with pancreatic cancer. Eight patients in the HPC group (40%) 
and 8 in the OPC group (20%) had diabetes mellitus at the time 
of diagnosis. Seven patients in the HPC group (35%) and 12 in 
the OPC group (30%) were smokers. Only 1 patient in the OPC 
Table 1. Baseline Characteristics and Presenting Symptoms of the 
HPC and OPC Groups
HPC, No. (%) 
(n=20)
OPC, No. (%) 
(n=40)
p-value
Age, median (range), yr 64 (47-82)    65 (42-86)
Sex, M:F 2.3:1 2.3:1
Abdominal pain 7 (35.0) 23 (57.5) NS
Weight loss 8 (40.0) 14 (35.0) NS
Serum CA 19-9, median (range), 
U/mL
234 
(0.1-8,140)
287 
(1.1-234,861)
NS
Presenting symptoms
  Jaundice -   4 (10.0) NS
  Anorexia 1 (5.0) 2 (5.0) NS
  Back pain   4 (20.0) 5 (2.5) NS
  Dizziness - 1 (2.5) NS
  Abdominal distension 1 (5.0) 1 (2.5) NS
  Weakness 1 (5.0) - NS
  Palpable mass 1 (5.0) - NS
  No symptom   6 (30.0) - 0.031
HPC, Health Promotion Center; OPC, Outpatient Clinic; NS, not sig-
nificant.
Table 2. Comparison of Risk Factors between the HPC and OPC 
Groups
Variable
HPC, No. (%)
 (n=20)
OPC, No. (%)
 (n=40)
p-value
DM 8 (40)   8 (20) NS
Smoking 7 (35) 12 (30) NS
BMI, kg/m
2 25.1 (20.6-29.5) 22.65 (16.6-33.3) 0.009
Chronic pancreatitis -   1 (2.5) NS
Familial history of 
pancreatic cancer
-- N S
HPC, Health Promotion Center; OPC, Outpatient Clinic; DM, diabetes 
mellitus, BMI, body mass index; NS, not significant.196  Gut and Liver, Vol. 5, No. 2, June 2011
group had a past medical history of chronic pancreatitis. None 
of the patients in either group had a family history of pancreatic 
cancer. There was no significant difference in the risk factors 
between the two groups except for the BMI. In the HPC group, 
the BMI was statistically higher than in the OPC group (25.1 kg/
m
2 vs 22.65 kg/m
2, p=0.009). 
2. Modalities with initial suspicion of pancreatic cancer
Among the 20 patients in the HPC group that underwent 
abdominal ultrasonography, 10 patients (n=10/20, 50%) were 
initially suspected of pancreatic cancer with abnormal ultraso-
nographic (USG) findings. Among the 17 patients in the HPC 
group that had serum CA 19-9 measured, 9 patients (n=9/17, 
53%) were initially suspected of having pancreatic cancer with 
elevated serum CA 19-9. Fourteen out of 17 patients had el-
evated serum CA 19-9 (median value, 361.5 U/mL; range, 43.3 
to 8,140 U/mL); 5 patients had abnormal findings on the USG 
at the same time. One patient (n=1/1, 100%) was initially sus-
pected to have pancreatic cancer based on an abnormal com-
puted tomography (CT). The patient reported severe epigastric 
pain and weight loss at the time of health screening, and ab-
dominal CT was performed. The serum CA 19-9 levels and USG 
findings were normal. On the other hand, more than half of the 
OPC patients were evaluated initially with CT because they were 
suspected of having pancreatic cancer at their primary medi-
cal institutions. Also, among the 37 patients in OPC group that 
had serum CA 19-9 measured initially, 27 patients had elevated 
serum CA 19-9 (median value, 1,170 U/mL; range, 44.9 to 
234,867 U/mL).
For the HPC group, the abnormal findings on the USG were 
focal lesions of the pancreas (7/20, 35%) and pancreatic duct 
dilatation (2/20, 10%). In addition, liver metastasis was detected 
by USG in one patient. 
The HPC group was divided into two groups: patients with 
normal USG findings (n=10) and patients with abnormal USG 
findings (n=10) (Table 3). There was no significant difference 
between the two groups with regard to tumor size, stage and lo-
cation. However, the BMI of patients with abnormal USG find-
ings was higher than in patients with normal abdominal USG 
findings (p=0.001). 
3. Prognosis
For the HPC group, 15% had stage I, 30% had stage II, 35% 
had stage III, and 20% had stage IV disease by the AJCC TNM 
Table 3. Characteristics of Patients with Abnormal Ultrasonographic 
Findings in the HPC Group
Abnormal ultrasonographic 
findings
p-value
Yes (n=10) No (n=10)
Symptoms, n 9 5 0.051
Elevated CA 19-9, n 7  9 0.264
BMI (median) 26.7 (23.0-29.5)  22.8 (20.6-26.7) 0.001
Size, mm 44±23.8 32.1±20.2 0.244
Stage (median stage) III II 0.274
  I, n 1  2
  II, n 2 5
  III, n 5 1
  IV, n 2 2
Location 0.513
  Head, n  4 2
  Body, n 4 4
  Tail, n 2 4
HPC, Health Promotion Center; BMI, body mass index.
Fig. 1. Comparison of pancreatic cancer stage between the Health 
Promotion Center (HPC) and Outpatient Clinic (OPC) groups based on 
American Joint Committee on Cancer (AJCC) TNM classification. 
Table 4. Comparison of Prognoses between the HPC and OPC Groups
HPC (n=20) OPC (n=40) p-value
Curative resection, n (%)
Median survival (range), mo
3-yr survival rate, n (%)
12/20 (60)
14.5 (1-70)
  4/20 (20)
10/40 (25)
    4 (1-136)
6/40 (15) 
0.011
0.000
0.624
HPC, Health Promotion Center; OPC, Outpatient Clinic.
Table 5. Differences between Symptomatic and Asymptomatic Pa-
tients in the HPC Groups
Symptomatic 
(n=14)
Asymptomatic 
(n=6)
p-value
Stage, n 0.590
  I 3 0
  II 4 3
  III 4 2
  IV 3 1
Curative resection, n (%) 7/14 (50) 5/6 (83) 0.163
Median survival (range), mo    13.5 (1-70)   21.0 (2-49) 0.260
3-yr survival rate, n (%) 2/14 (14) 2/6 (33) 0.329
HPC, Health Promotion Center.Kim ER, et al: Is Health Screening Beneficial for Pancreatic Cancer?  197
classification. For the OPC group, 7.5% had stage I, 20% had 
stage II, 20% had stage III, and 52.5% had stage IV disease (Fig. 
1). The curative resection rate was higher in the HPC group 
(n=12/20, 60%) than in OPC group (n=10/40, 25%, p=0.011). 
The median survival was longer in HPC group (14.5 months) 
than in the OPC group (4 months, p=0.000). However, there was 
no significant difference in the 3-year survival rate between the 
two groups (HPC group vs OPC, 20% vs 15.0%, p=0.624) (Table 
4). 
When the HPC group was divided into symptomatic and as-
ymptomatic groups at the time of diagnosis, tumor stage, cura-
tive resection rate, median survival, and 3-year survival rate did 
not significantly differ (Table 5). 
DISCUSSION
Pancreatic cancer remains a lethal malignancy. Due to the 
rapid progression of pancreatic cancers, early detection through 
screening will be required to improve long-term outcomes.
8 In 
this respect, pancreatic neoplasias may meet some of the World 
Health Organization criteria for principles of screening. Sohn 
et al.
9 showed that survival was markedly better in patients 
that had small tumors, negative resection margins, and no 
lymph node involvement. Ariyama et al. reported a postopera-
tive 5-year cumulative survival rate of 100% for patients with 
tumors less than 1 cm in size.
10,11 These data provide some evi-
dence that early detection through screening may improve the 
long-term outcome for adenocarcinoma of the pancreas. How-
ever, since the prevalence of pancreatic cancer remains too low (8 
to 12 per 100,000), it would not be cost effective and the yield 
of screening would be extremely low in the general popula-
tion.
4,12 At present, as it is known that 3% to 16% of pancreatic 
cancers are either syndromic or familial, patients with known 
genetic syndromes predispose them to the disease or with a 
strong familial history may be offered screening and surveil-
lance in an attempt to detect pancreatic neoplasia at a curable 
stage.
8 Whereas routine check-up for detecting of early pancre-
atic cancer in general population was not recommended to date. 
This study focused on a general health screening program. Ab-
dominal USG which was usually included in the health screen-
ing program, screened several diseases related with hepatobili-
ary system, kidney and other organ of the abdominal cavity, 
not only for pancreatic cancers. Therefore, the cost-effectiveness 
for the detection of pancreatic cancer is not an important issue 
under this screening program. Moreover, there is a chance that 
the increasing volume of health screening improves the detec-
tion rate of early pancreatic cancer.
A remarkable thing about this study was that the curative 
resection rate and median survival were greater for the pan-
creatic cancer patients diagnosed at the HPC compared to pa-
tients diagnosed at the OPC. In addition, pancreatic cancer was 
detected at an earlier stage in the HPC group than in the OPC 
group. However there was a limitation to detect pancreatic can-
cer as early as the long-term survival was possible. In order to 
improve long-term survival, pancreatic cancer must be detected 
when patients are asymptomatic and the tumor is small (≤2 cm) 
and classified as T1 stage. However, in this study, only 30% of 
the HPC group was asymptomatic and 15% were classified as T1 
stage. So, the long-term survival was not significantly improved 
in the HPC group compared to the OPC group.
A common problem in patients with pancreatic cancer is 
delayed diagnosis. This delay in diagnosis is largely due to the 
fact that abdominal pain and jaundice, which are the main 
symptoms of pancreatic cancer, appear relatively late during the 
course of the disease when the tumor is already at an advanced 
stage.
13,14 In this study, 30% of patients with pancreatic cancer 
diagnosed at the HPC had no symptoms, and all patients diag-
nosed at the OPC had symptoms at the time of diagnosis. Most 
of the patients with symptoms presented with typical symptoms 
such as abdominal pain, back pain, weight loss, and jaundice. 
For the HPC group, asymptomatic patients were shown bet-
ter curative resection rate and survival rate than symptomatic 
patients, but unfortunately, this difference was not statistically 
significant (Table 5). A large series of asymptomatic patients 
with pancreatic cancer are needed for further study. 
In the present study, there were 6 missed cases judged as 
benign condition of pancreas at the health promotion center, 
however diagnosed with pancreatic cancer within 1 year. The 
median period for a delayed diagnosis was 7.5 months. On the 
initial USG findings at the HPC, 5 of 6 cases were normal and 
the remaining one had pancreatic duct dilatation. These cases 
suggest that patients with abnormal USG findings such as pan-
creatic duct dilatation, require further workup particularly if the 
patient is of advanced ages. In the 5 patients with serum CA 
19-9 measured at the time of screening, all had normal level 
of CA19-9. The remaining one measured serum CA 19-9 at 
the time of diagnosis of pancreatic cancer and serum CA 19-9 
was elevated. Although the positive predictive value CA 19-9 
for detecting pancreatic cancer was very low, patients with an 
elevated CA 19-9 require careful follow-up. However, there still 
remains a possibility that abdominal USG and serum CA 19-9 
may miss a significant number of cases of pancreatic cancer.
As shown in these missed cases, another problem in patients 
with pancreatic cancer is limited accuracy of available screening 
tests for detection of small pancreatic cancer. The tools for diag-
nosis of pancreatic cancer can be categorized as serologic bio-
markers such as CA 19-9 and imaging techniques. The results 
of this study showed that nearly half of the patients in the HPC 
group were diagnosed with pancreatic cancer by only increased 
serum CA 19-9; there were no definite abnormal lesion in pan-
creas on their abdominal USG findings. Five out of 9 patients 
that were initially suspected of having pancreatic cancer with 
elevated serum CA 19-9, had no symptoms. These results looked 
as if serum CA 19-9 was effective tests to detect small pancre-198  Gut and Liver, Vol. 5, No. 2, June 2011
atic cancer in an asymptomatic population. However, caution is 
necessary for the interpretation of increased serum CA 19-9 as 
a marker for pancreatic cancer. Recent reports in asymptomatic 
subjects demonstrated that the incidence of carcinoma in as-
ymptomatic subjects with elevated CA 19-9 was very low (2.8%, 
10/353) and among them, subjects with pancreatic cancer were 
only 1.1% (4/353).
15 Other studies have reported that the posi-
tive predictive value CA 19-9 for detecting pancreatic cancer 
was only 0.9% in the asymptomatic population.
16-18
Also, in this study, half of the patients in the HPC group were 
initially suspected of having pancreatic cancer with abnormal 
USG findings. However, as mentioned earlier, the other half in 
the HPC group had normal USG findings. Between patients with 
normal and abnormal USG findings in the HPC group, there 
was no significant difference except for the BMI. Contrary to 
expectations, the BMI was higher in patients with abnormal 
USG findings than in patients with normal USG findings. But, 
the BMI was not always correlated with abdominal obesity and 
the sonographic view could be affected by bowel gas too. Of 
all the imaging studies, the endoscopic ultrasound (EUS) and 
helical CT scans are the most sensitive imaging modalities for 
detecting pancreatic tumor.
4 Some studies reported that the EUS 
was useful for surveillance in high risk group patients.
4,6 But, 
using the EUS directly to screen the general population may be 
problematic due to invasiveness of methods and limited avail-
abiliaty.
3,19 Multi-detector CT is the current preferred abdominal 
imaging test for pancreatic disease, including the diagnosis and 
staging of pancreatic cancer.
13,20 But, because of the concern for 
repeated exposure to radiation, the role of the CT in screening 
for small pancreatic cancers remains to be established.
3
The limitations of the present study include the following. 
First, the HPC group did not precisely represent the general 
population because they were interested in health enough to 
have private health screening and some of them had presenting 
symptoms at the time of their checkups. Second, since this hos-
pital is a tertiary referral center, the patients that registered in 
the OPC group likely reflects a selection bias. Finally, the target 
number of pancreatic cancer patients diagnosed at the health 
promotion center was small. But considering the incidence of 
pancreatic cancer in the general population,
21,22 the number of 
cases identified in the HPC group was not small. 
In conclusion, general health screening is somewhat helpful 
for improving the curative resection rate and median survival 
of patients with pancreatic cancer detected as part of a general 
screening visit. However, there is a limitation to detect early 
enough to improve long-term survival. Also general health 
screening misses a significant portion of pancreatic cancer. 
Therefore, more sensitive and cost-effective screening tool is 
needed to improve the detection, early treatment and outcome 
of patients with pancreatic cancer.
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